Glaukos Has Completed Enrollment And Randomization In Its Second Phase 3 Trial For Epioxa; This Trial Results Together With The First Phase 3 Trial Is Expected To Support Glaukos' Targeted NDA Submission For Epioxa By The End Of 2024
Portfolio Pulse from Benzinga Newsdesk
Glaukos has completed enrollment and randomization in its second Phase 3 trial for Epioxa. The results of this trial, along with the first Phase 3 trial, are expected to support Glaukos' targeted NDA submission for Epioxa by the end of 2024.
June 05, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Glaukos' completion of enrollment in the second Phase 3 trial for Epioxa is a positive step towards their targeted NDA submission by the end of 2024.
The completion of enrollment and randomization in the second Phase 3 trial for Epioxa is a significant milestone for Glaukos. This progress, along with the results from the first Phase 3 trial, will support their targeted NDA submission by the end of 2024. This positive development is likely to have a short-term positive impact on Glaukos' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100